Direct answer: Rare disease recruitment inverts the normal math: instead of filtering a huge population down, you’re hunting for a small population that’s scattered, often misdiagnosed, and exhausted by false hope. What works is reach broad enough to find undiagnosed and unconnected patients, creative that speaks the community’s language, screening rigorous enough to protect the tiny pool of site capacity, and white-glove handling of every single candidate, because in rare disease there is no such thing as a disposable referral.

Why rare disease recruitment fails the usual playbook

In a common condition, losing a referral costs you nothing; there are thousands more. In rare disease, every qualified patient you fumble might be one of a few hundred on the continent. Registries and advocacy groups reach the organized center of the community, but a large share of eligible patients aren’t in any registry, see a specialist rarely or never, and may not even carry the right diagnosis yet. Reaching them takes broad, well-targeted advertising with creative a patient or caregiver instantly recognizes as their life.

What we’ve learned works

Lead with the story, not the study

Rare disease communities have been marketed to before, and burned before. Creative that opens with lived experience (the symptoms, the diagnostic odyssey, the daily workarounds) earns the click that protocol language never will. This is personal for us: Clinical Enrollment exists because a trial for our founder’s rare retinal disease failed to find enough patients. Good science. Not enough people.

Screen hard, even when patients are scarce

The temptation in rare disease is to send sites everyone who raises a hand. Resist it. Site capacity in rare disease is even scarcer than patients, and specialist sites lose faith in a pipeline that wastes their screening slots. Double-screening still applies; it’s how 89% of the patients we walk into sites end up signing the consent form.

Treat every candidate like the last one

Travel logistics, records retrieval, caregiver coordination, and steady human contact. Our site relations team speaks with each patient 3.7 times on average before they ever visit a site. In rare disease that number runs higher, because the distances are longer and the stakes, for the family, are total.

Work with the community, not around it

Advocacy organizations, patient groups, and specialist networks aren’t media channels, they’re gatekeepers of trust who’ve watched studies come and go. Engage them early, honestly, and with something to offer their community beyond your screener link.

What we won’t promise

Anyone who quotes you a confident enrollment date for an ultra-rare study before seeing real prevalence and site geography is guessing with your timeline. The honest version: rare disease enrollment forecasts start wide and narrow as screening data arrives. What a good partner commits to is the machine (reach, screening, follow-through) and full visibility into what it’s finding, week by week.

Frequently asked questions